Therapeutic implications of oral hypoglycaemic agents on the enteroinsular axis in type 2 diabetes

Completed

• Conditions: Non-insulin-dependent diabetes mellitus; Nutritional, Metabolic, Endocrine; Type 2 diabetes

• Registration Number: ISRCTN37245053
• Lead Sponsor: Royal Victoria Hospital (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-11-28
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Both males and females, aged greater than 18 years
2. Type 2 diabetes controlled by diet or a single oral hypoglycaemic agent
3. HbA1c less than 7.5%
4. No significant liver, cardiac or renal problems (creatinine greater than 150 mmol/l)

Exclusion Criteria

Type 2 diabetes on two or more hypoglycaemic agents or requiring insulin.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood samples were collected from the participants at -5, 0, 30, 60, 120, 180 and 240 minutes for the measurements of the following: <br>1. Glucose <br>2. Insulin <br>3. C-peptide <br>4. DPPIV activity <br>5. GLP-1

Secondary Outcome Measures

Name	Time	Method
Serum metformin levels, measured by high performance liquid chromatography on blood samples collected at 0, 60, 120 and 240 minutes.